CH661868A5 - Ganzzellen- oder zellwandpraeparate fuer die radio- oder chemotherapie von tumoren. - Google Patents
Ganzzellen- oder zellwandpraeparate fuer die radio- oder chemotherapie von tumoren. Download PDFInfo
- Publication number
- CH661868A5 CH661868A5 CH2100/81A CH210081A CH661868A5 CH 661868 A5 CH661868 A5 CH 661868A5 CH 2100/81 A CH2100/81 A CH 2100/81A CH 210081 A CH210081 A CH 210081A CH 661868 A5 CH661868 A5 CH 661868A5
- Authority
- CH
- Switzerland
- Prior art keywords
- granulosum
- mice
- cell
- chemotherapy
- tumors
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 34
- 206010028980 Neoplasm Diseases 0.000 title claims description 32
- 210000004027 cell Anatomy 0.000 title claims description 28
- 210000002421 cell wall Anatomy 0.000 title claims description 22
- 238000002512 chemotherapy Methods 0.000 title claims description 17
- 241001464975 Cutibacterium granulosum Species 0.000 claims description 61
- 241001464974 Cutibacterium avidum Species 0.000 claims description 22
- 241000186427 Cutibacterium acnes Species 0.000 claims description 19
- 239000000725 suspension Substances 0.000 claims description 17
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 11
- 239000002953 phosphate buffered saline Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 8
- 239000008363 phosphate buffer Substances 0.000 claims description 7
- 229940055019 propionibacterium acne Drugs 0.000 claims description 6
- 229940055009 propionibacterium avidum Drugs 0.000 claims description 6
- 238000001959 radiotherapy Methods 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 3
- 239000011149 active material Substances 0.000 claims description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 60
- 210000000952 spleen Anatomy 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 13
- 210000001185 bone marrow Anatomy 0.000 description 13
- 208000006268 Sarcoma 180 Diseases 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000001802 infusion Methods 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 241000186429 Propionibacterium Species 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 239000003978 infusion fluid Substances 0.000 description 4
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241001655324 Propionibacteriales Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010048038 Wound infection Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 208000020154 Acnes Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229940072358 xylocaine Drugs 0.000 description 2
- SWMBOMMGMHMOHE-MHLULTLJSA-N (2r,3r,4r,5r)-hexane-1,2,3,4,5,6-hexol;(2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SWMBOMMGMHMOHE-MHLULTLJSA-N 0.000 description 1
- ORRBHGDXBDFSFM-UHFFFAOYSA-N 1h-indole;nitric acid Chemical compound O[N+]([O-])=O.C1=CC=C2NC=CC2=C1 ORRBHGDXBDFSFM-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000595586 Coryne Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000187656 Eucalyptus cornuta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- -1 polyethylene lead Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3011461A DE3011461C2 (de) | 1980-03-25 | 1980-03-25 | Verwendung von Propionibakterien |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH661868A5 true CH661868A5 (de) | 1987-08-31 |
Family
ID=6098254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH2100/81A CH661868A5 (de) | 1980-03-25 | 1981-03-27 | Ganzzellen- oder zellwandpraeparate fuer die radio- oder chemotherapie von tumoren. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4647456A (enExample) |
| JP (1) | JPS57165319A (enExample) |
| AT (1) | AT371714B (enExample) |
| AU (1) | AU548596B2 (enExample) |
| BE (1) | BE888770A (enExample) |
| CA (1) | CA1197798A (enExample) |
| CH (1) | CH661868A5 (enExample) |
| DE (1) | DE3011461C2 (enExample) |
| FR (1) | FR2505186A1 (enExample) |
| GB (1) | GB2098478B (enExample) |
| NL (1) | NL189947C (enExample) |
| NO (1) | NO162079C (enExample) |
| SE (1) | SE450088B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4678773A (en) * | 1983-08-26 | 1987-07-07 | Chugai Seiyaku Kabushiki Kaisha | Antitumor agent |
| DE3817762A1 (de) * | 1988-05-26 | 1989-11-30 | Sanum Kehlbeck Gmbh & Co Kg | Immunstimulierendes mittel aus propionibakterien sowie verfahren zur herstellung desselben |
| IL101410A0 (en) * | 1992-03-29 | 1992-11-15 | Era Masis Ltd | Formulation for the treatment of cancer |
| DE19630230A1 (de) * | 1996-07-26 | 1998-01-29 | Bayer Ag | Herstellung immunstimulierender Mittel auf Basis von Propionibakterien |
| FR2764802A1 (fr) * | 1996-12-24 | 1998-12-24 | Standa Lab Sa | Composition adsorbable renfermant des bacteries propioniques susceptible de degager du monoxyde d'azote dans le tube digestif humain ou animal |
| AU736450B2 (en) | 1997-08-05 | 2001-07-26 | Bioniche Urology Ip Inc. | Composition and method for regulating cell proliferation and cell death |
| EP1230920B1 (en) | 1999-10-19 | 2006-07-19 | Meiji Dairies Corporation | Use of food materials in preventing and ameliorating metabolic bone diseases |
| DK1238070T3 (da) * | 1999-12-13 | 2007-12-03 | Bioniche Life Sciences Inc | Terapeutisk anvendelige syntetiske oligonucleotider |
| JP4215429B2 (ja) * | 1999-12-28 | 2009-01-28 | バイオニケ ライフ サイエンシーズ インコーポレイテッド | 癌治療におけるヒアルロン酸 |
| GB2623078B (en) * | 2022-10-03 | 2025-04-16 | Univ Brunel | Prevention and/or treatment of wound infection |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2269961B1 (enExample) * | 1974-05-06 | 1978-03-24 | Anvar | |
| FR2269962B1 (enExample) * | 1974-05-06 | 1978-02-03 | Anvar | |
| JPS5215894A (en) * | 1975-07-29 | 1977-02-05 | Yuichi Yamamura | Process for preparing a substance possessing biological actions |
| JPS5946206B2 (ja) * | 1975-10-08 | 1984-11-10 | （株） 目黒研究所 | 免疫学的活性を有する非病原性好気性コリネバクテリウム培養物の製造法 |
| JPS52108091A (en) * | 1976-03-03 | 1977-09-10 | Kowa Co | Production of antiitumor substance |
| JPS5411233A (en) * | 1977-06-28 | 1979-01-27 | Asahi Chem Ind Co Ltd | Anitidote |
| JPS5513204A (en) * | 1978-06-28 | 1980-01-30 | Mitsui Toatsu Chem Inc | Active compound having delayed allergic activity and anticarcinogenic activity, and its preparation |
| JPS55114290A (en) * | 1979-02-27 | 1980-09-03 | Mitsui Toatsu Chem Inc | Substance with antitumorigenic activity, its production and medical preparation |
-
1980
- 1980-03-25 DE DE3011461A patent/DE3011461C2/de not_active Expired
-
1981
- 1981-03-10 NO NO810815A patent/NO162079C/no not_active IP Right Cessation
- 1981-03-12 SE SE8101582A patent/SE450088B/sv not_active IP Right Cessation
- 1981-03-13 AT AT0118981A patent/AT371714B/de not_active IP Right Cessation
- 1981-03-24 NL NLAANVRAGE8101452,A patent/NL189947C/xx not_active IP Right Cessation
- 1981-03-27 CH CH2100/81A patent/CH661868A5/de not_active IP Right Cessation
- 1981-04-02 JP JP56050014A patent/JPS57165319A/ja active Granted
- 1981-05-06 CA CA000376972A patent/CA1197798A/en not_active Expired
- 1981-05-07 AU AU70242/81A patent/AU548596B2/en not_active Ceased
- 1981-05-08 FR FR8109265A patent/FR2505186A1/fr active Granted
- 1981-05-12 BE BE0/204763A patent/BE888770A/fr not_active IP Right Cessation
- 1981-05-15 GB GB8114915A patent/GB2098478B/en not_active Expired
-
1985
- 1985-01-03 US US06/688,278 patent/US4647456A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| GB2098478B (en) | 1985-02-20 |
| ATA118981A (de) | 1982-10-15 |
| CA1197798A (en) | 1985-12-10 |
| NO162079C (no) | 1989-11-01 |
| NL189947B (nl) | 1993-04-16 |
| NL189947C (nl) | 1993-09-16 |
| BE888770A (fr) | 1981-11-12 |
| DE3011461A1 (de) | 1981-10-01 |
| US4647456A (en) | 1987-03-03 |
| SE8101582L (sv) | 1982-09-13 |
| AU548596B2 (en) | 1985-12-19 |
| FR2505186B1 (enExample) | 1984-10-12 |
| NO810815L (no) | 1982-09-13 |
| AU7024281A (en) | 1982-11-11 |
| FR2505186A1 (fr) | 1982-11-12 |
| JPS57165319A (en) | 1982-10-12 |
| JPH0355448B2 (enExample) | 1991-08-23 |
| NO162079B (no) | 1989-07-24 |
| NL8101452A (nl) | 1982-10-18 |
| DE3011461C2 (de) | 1986-10-30 |
| AT371714B (de) | 1983-07-25 |
| GB2098478A (en) | 1982-11-24 |
| SE450088B (sv) | 1987-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69116377T2 (de) | Mycobacterium vaccae in der behandlung von uveitis | |
| DE3833319C2 (enExample) | ||
| DE69526935T2 (de) | Verwendung von mycobacterium zur tumorbehandlung | |
| DE69309915T2 (de) | Mycobacterium Vaccae zur Behandlung von langwierigen Autoimmunerkrankungen | |
| DE69418183T2 (de) | Immunotherapeutische zubereitung | |
| Jaffe | The reticulo-endothelial system in immunity | |
| DE69213943T2 (de) | Kurzzeitige stimulierung von lymphozyten mit anti-cd3 antikörpern um ihre in vivo aktivität zu steigern | |
| DE3011461C2 (de) | Verwendung von Propionibakterien | |
| EP0173241B1 (de) | Vakzine zur Behandlung der Harnwegsinfektionen | |
| DE3887686T2 (de) | Bakterielle zubereitung für die prophylaxe und behandlung von entzuendungen und allergischen beschwerden. | |
| CH651210A5 (de) | Verfahren zur herstellung einer antikoerper enthaltenden milch zur bekaempfung bakterieller infektionen des magen-darm-traktes. | |
| DE69026371T2 (de) | Heilmittel und verfahren zur inhibierung der vaskularisierung von tumoren | |
| Balner et al. | Reduction of X-ray lethality in mice by agents affecting the reticuloendothelial system | |
| DE69021791T2 (de) | Verwendung eines phagozytise-aktievierenden Stoffes : LPS oder IL-2 zur Herstellung eines Arzneimittels zur Behandlung von Staphylococcus-aureus-Infektionen bei Kühen. | |
| DE2212277C3 (de) | Verfahren zur Herstellung einer Totvaccine gegen infektiöse atrophische Rhinitis der Schweine | |
| DE3504940C2 (de) | Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel | |
| DE2738652B2 (de) | Lactobacillus-Präparat und seine Verwendung bei der Bekämpfung bakterieller Infektionen und Entzündungen | |
| Rurangirwa et al. | Treatment of contagious caprine pleuropneumonia | |
| DE60213785T2 (de) | Saponin inaktivierte mykoplasma impfstoffe | |
| CH639133A5 (de) | Verfahren zur herstellung einer antitumor wirksamen substanz mit immunostimulierender wirkung. | |
| Jensen et al. | Influence of endotoxin on resistance of mice to intraperitoneal infection with human oral bacteria | |
| DE2152112A1 (de) | Antitumor- und Vaccinzubereitungen | |
| Topley et al. | Further Observations on the Rôle of the Twort-d'Herelle Phenomenon in the Epidemic Spread of Mouse-typhoid. 1 | |
| Jones | The effect of storage in slurry on the virulence of Salmonella dublin | |
| DE2700338C2 (de) | Parenteral injizierbarer Impfstoff für Schweine gegen Infektionen von Bordetella bronchiseptica sowie Verfahren zum Herstellen dieses Impfstoffes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PFA | Name/firm changed |
Owner name: DR. MADAUS GMBH & CO. |
|
| PUE | Assignment |
Owner name: SANUM-KEHLBECK GMBH & CO. KG |
|
| PUE | Assignment |
Owner name: SANUM-KEHLBECK GMBH & CO. KG TRANSFER- PROF. DR. D |
|
| PL | Patent ceased |